Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FCM-NPs
- Development stage
- Preclinical
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
**FCM-NPs** is an experimental ovarian-cancer nano-vaccine composed of a fusion cell membrane derived from dendritic cells and ovarian-cancer cells, coated onto poly(lactic-co-glycolic acid) nanoparticles encapsulating CpG oligodeoxynucleotide. The fusion membrane is intended to combine a broad set of ovarian-tumor antigens with dendritic-cell antigen-presentation and co-stimulatory features, while CpG oligodeoxynucleotide activates Toll-like receptor 9 to enhance dendritic-cell maturation and cytotoxic T-cell responses. In mouse subcutaneous, patient-derived xenograft, and peritoneal-metastasis ovarian-cancer models, the vaccine delayed tumor growth and reduced metastatic tumor burden. It remains a preclinical research-stage personalized cancer-vaccine approach.
- Other names
- DC/OC FCM-NPs nano-vaccineFCM@NPsfusion cell membrane nano-vaccine
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on FCM-NPs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FCM-NPs.